Scientific Reports (Apr 2021)

Consumption of caffeinated beverages and kidney function decline in an elderly Mediterranean population with metabolic syndrome

  • Andrés Díaz-López,
  • Indira Paz-Graniel,
  • Verónica Ruiz,
  • Estefanía Toledo,
  • Nerea Becerra-Tomás,
  • Dolores Corella,
  • Olga Castañer,
  • J. Alfredo Martínez,
  • Ángel M. Alonso-Gómez,
  • Julia Wärnberg,
  • Jesús Vioque,
  • Dora Romaguera,
  • José López-Miranda,
  • Ramon Estruch,
  • Francisco J. Tinahones,
  • José Lapetra,
  • Luís Serra-Majem,
  • Aurora Bueno-Cavanillas,
  • Josep A. Tur,
  • Vicente Martín Sánchez,
  • Xavier Pintó,
  • Miguel Delgado-Rodríguez,
  • Pilar Matía-Martín,
  • Josep Vidal,
  • Clotilde Vázquez,
  • Lidia Daimiel,
  • Tania Fernandez Villa,
  • Emilio Ros,
  • Sonia Eguaras,
  • Nancy Babio,
  • Jose V. Sorlí,
  • Albert Goday,
  • Itziar Abete,
  • Lucas Tojal Sierra,
  • Francisco Javier Barón-López,
  • Laura Torres-Collado,
  • Marga Morey,
  • Antonio Garcia-Rios,
  • Rosa Casas,
  • María Rosa Bernal-López,
  • José Manuel Santos-Lozano,
  • Adela Navarro,
  • Jose I. Gonzalez,
  • María Dolores Zomeño,
  • Maria Angeles Zulet,
  • Jessica Vaquero Luna,
  • Raul Ramallal,
  • Montse Fitó,
  • Jordi Salas-Salvadó

DOI
https://doi.org/10.1038/s41598-021-88028-7
Journal volume & issue
Vol. 11, no. 1
pp. 1 – 13

Abstract

Read online

Abstract It remains unclear whether caffeinated beverages could have deleterious renal effects in elderly population with underlying comorbid conditions. We investigated the associations between coffee, tea, or caffeine intake and 1-year changes in glomerular filtration rate (eGFR) in a large Spanish cohort of overweight/obese elderly with metabolic syndrome (MetS). This prospective analysis includes 5851 overweight/obese adults (55–75 years) with MetS from the PREDIMED-Plus study. We assessed coffee, tea, and caffeine consumption from a validated food-frequency questionnaire and creatinine-based eGFR using the Chronic Kidney Disease Epidemiology Collaboration equation. Multivariate-adjusted regression models were applied to test associations between baseline coffee, tea, or caffeine intake and 1-year eGFR changes. Caffeinated coffee (> 2 cups/day) and tea (at least 1 cup/day) drinkers had 0.88 and 0.93 mL/min/1.73 m2 greater eGFR decrease respectively, compared to those with less than 1 cup/day of coffee consumption or non-tea drinkers. Furthermore, caffeinated coffee consumption of > 2 cups/day was associated with 1.19-fold increased risk of rapid eGFR decline > 3 mL/min/1.73 m2 (95% CI 1.01–1.41). Similarly, individuals in the highest (median, 51.2 mg/day) tertile of caffeine intake had a 0.87 mL/min/1.73 m2 greater eGFR decrease. Decaffeinated coffee was not associated with eGFR changes. In conclusion, higher consumption of caffeinated coffee, tea, and caffeine was associated with a greater 1-year eGFR decline in overweight/obese adults with MetS.